{
    "clinical_study": {
        "@rank": "166303", 
        "arm_group": [
            {
                "arm_group_label": "Enhanced external counterpulsation (EECP)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Subjects not receiving EECP", 
                "arm_group_type": "No Intervention", 
                "description": "Control group to measure data from experimental group against."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to investigate whether enhanced external counterpulsation (EECP)\n      therapy for 7 consecutive weeks will improve cerebral blood flow and possibly over time\n      enhance or slow down breakdown of cognitive function in patients diagnosed with mild\n      cognitive impairment (MCI)."
        }, 
        "brief_title": "Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Mild Cognitive Impairment", 
        "condition_browse": {
            "mesh_term": "Cognition Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An adult between 18 and 85 years of age.\n\n          -  Has been evaluated to have a CDR (Clinical Dementia Rating) Score of 0.5\n\n          -  Male or female (if female must be postmenopausal for at least 1 year, surgically\n             sterile or using an effective form of contraception).\n\n          -  Able to speak and read English.\n\n          -  Willing to comply with study specific instructions, and complete all study procedures\n             according to protocol.\n\n          -  Able to understand study rationale and sign informed consent.\n\n        Exclusion Criteria:\n\n          -  Diagnosed with glaucoma\n\n          -  History of developing adverse effects to ophthalmic dilating agents (phenylephrine or\n             tropicamide).\n\n          -  Currently taking warfarin and dabigatran (Pradaxa).\n\n          -  History of having arrhythmias - can interfere with EECP triggering.\n\n          -  Subject has bleeding diathesis.\n\n          -  Subject has active thrombophlebitis.\n\n          -  Subject has severe lower extremity vaso-occlusive disease.\n\n          -  Subject has a documented aortic aneurysm requiring surgical repair.\n\n          -  Subject is pregnant.\n\n          -  Subject with blood pressure higher than 180/110 mmHg.\n\n          -  Subject with a heart rate more than 120 bpm.\n\n          -  Subject with high risk of complications from increased venous return.\n\n          -  Subject with clinically significant valvular disease.\n\n          -  Subjects with severe vascular disease as established by the Hachinski Ischemic Index.\n\n          -  Subjects with pacemakers and other metallic implantable devices."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659398", 
            "org_study_id": "13106"
        }, 
        "intervention": {
            "arm_group_label": "Enhanced external counterpulsation (EECP)", 
            "description": "A noninvasive neuroimaging technique.  Administration of 35 hours EECP therapy over a 7 week period.  EECP to be administered for 1 hour, 5 times a week.", 
            "intervention_name": "External Counterpulsation (EECP)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Alzheimer's Disease", 
            "cerebral blood flow", 
            "ophthalmic blood flow", 
            "blood viscosity"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "link": {
            "description": "University of Kansas Clinical Pharmacology Homepage", 
            "url": "http://www2.kumc.edu/internalmedicine/clinpharm_geninfo.html"
        }, 
        "location": {
            "contact": {
                "email": "JDUTTON@kumc.edu", 
                "last_name": "Julie-Ann Dutton, MS, RD", 
                "phone": "913-588-4064"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "investigator": {
                "last_name": "Patrick Moriarty, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients", 
        "overall_contact": {
            "email": "JDUTTON@kumc.edu", 
            "last_name": "Julie-Ann Dutton, MS, RD", 
            "phone": "(913) 588-4064"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Patrick Moriarty, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in cognitive function measured using the Alzheimer's Disease Assessment Scale-cognitive sub-scale (ADAS-cog).  Scale is used to determine patient's mental status.  The scale has 11 parts and scores range from 0 (no impairment) to 70 (severe impairment).", 
            "measure": "Change in Cognitive Function", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 7, 6 Month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659398"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kansas Medical Center Research Institute", 
            "investigator_full_name": "Patrick Moriarty, MD, FACP, FACC", 
            "investigator_title": "Director, Clinical Pharmacology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Ophthalmic blood flow (OBF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 7"
            }, 
            {
                "measure": "Change in Blood Viscosity", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 7"
            }, 
            {
                "measure": "Cholesterol composition of the blood", 
                "safety_issue": "No", 
                "time_frame": "Baseline to week 7"
            }
        ], 
        "source": "University of Kansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Patrick Moriarty, MD, FACP, FACC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}